The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma.
 
Kirit Singh
No Relationships to Disclose
 
Matthew Foster
No Relationships to Disclose
 
Elizabeth S. Miller
No Relationships to Disclose
 
Simon Gregory
Consulting or Advisory Role - Pfizer (Inst)
Research Funding - Janssen (Inst)
 
Kent J. Weinhold
No Relationships to Disclose
 
David M. Ashley
Stock and Other Ownership Interests - Diverse Biotech; MAIA Biotechnology
Consulting or Advisory Role - Jackson Laboratory for Genomic Medicine; MAIA Biotechnology
Patents, Royalties, Other Intellectual Property - Methods for predicting tumor response to immunotherapy, U.S. Provisional application no. 62/787,508 filed January 2, 2019 Methods for predicting tumor response to immunotherapy, U.S. Provisional application no. 62/620,577 filed January 23, 2018
 
Annick Desjardins
Stock and Other Ownership Interests - ISTARI Oncology
Consulting or Advisory Role - Istari Oncology; Orbus Therapeutics
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Orbus Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - AU 2019247039 NEOADJUVANT CANCER TREATMENT; CA 2,892,183 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; Canada NEOADJUVANT CANCER TREATMENT; China NEOADJUVANT CANCER TREATMENT; EP 13856989.2 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; HK 15112399.5 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; JP 2020-554198 NEOADJUVANT CANCER TREATMENT; PCT/US2019/025402 NEOADJUVANT CANCER TREATMENT; South Korea 10-2020-7031272 NEOADJUVANT CANCER TREATMENT; US 15/428510 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; US 16/086,735 SEQUENTIAL ANTI-CANCER TREATMENT; US 16/505,771 ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS; US 17/016,699 ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS; US 17/044,645 NEOADJUVANT CANCER TREATMENT; US 62/651,470; US 62/823,277 NEOADJUVANT CANCER TREATMENT
 
Justin Low
No Relationships to Disclose
 
Katherine B. Peters
Consulting or Advisory Role - Sapience Therapeutics; SERVIER; Vivacitas Oncology
Research Funding - Abbvie; Agios; BioMimetix; Novocure; Sapience Therapeutics; SERVIER
Other Relationship - Eisai Europe
 
Erin Severance
No Relationships to Disclose
 
Denise Jaggers
No Relationships to Disclose
 
Henry S. Friedman
Stock and Other Ownership Interests - Cancer Expert Now; Diverse Biotech; ISTARI Oncology
Consulting or Advisory Role - Cancer Expert Now; Diverse Biotech; ISTARI Oncology
Patents, Royalties, Other Intellectual Property - Letters of Patent for Oncolytic Poliovirus for Human Tumors
 
Margaret O. Johnson
No Relationships to Disclose
 
Allan H. Friedman
Stock and Other Ownership Interests - ISTARI Oncology
 
Stephen T. Keir
No Relationships to Disclose
 
James Emmett Herndon
No Relationships to Disclose
 
Chuan-Yuan Li
Patents, Royalties, Other Intellectual Property - Use of anti-PCSK9 antibodies in cancer immunotherapy.
 
Peter E. Fecci
Consulting or Advisory Role - Monteris Medical
 
John H. Sampson
Stock and Other Ownership Interests - Annias Immunotherapeutics; ISTARI
Consulting or Advisory Role - Annias Immunotherapeutics; Insera Health; Medicenna
Patents, Royalties, Other Intellectual Property - Annias Immunotherapeutics - Equity, Licensed IP; Istari Oncology - Equity, Licensed IP; Neuronium - Equity, Optioned IP
 
Mustafa Khasraw
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Janssen; Lilly; Roche
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Specialised Therapeutics (Inst)
Travel, Accommodations, Expenses - Roche/Genentech